Latest Articles
Organon Discontinues Endometriosis Drug Development After Failed Phase 2 Trial - Femtech Insider
Organon Discontinues Endometriosis Drug Development After Failed Phase 2 Trial Femtech Insider
Published: July 2, 2025, 9:17 p.m.
Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test - MedCity News
Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test MedCity News
Published: July 2, 2025, 8:17 p.m.
AstraZeneca’s New Study on Durvalumab and Olaparib in Endometrial Cancer: Market Implications - TipRanks
AstraZeneca’s New Study on Durvalumab and Olaparib in Endometrial Cancer: Market Implications TipRanks
Published: July 2, 2025, 5:03 p.m.
Identification of key genes associated with infertile endometriosis based on bioinformatic analysis - Frontiers
Identification of key genes associated with infertile endometriosis based on bioinformatic analysis Frontiers
Published: July 2, 2025, 4:08 p.m.
Organon's non-hormonal endometriosis hope dashed - FirstWord Pharma
Organon's non-hormonal endometriosis hope dashed FirstWord Pharma
Published: July 2, 2025, 3:25 p.m.
Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset - Endpoints News
Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset Endpoints News
Published: July 2, 2025, 2:34 p.m.
Women with endometriosis-associated infertility are more likely to become pregnant, study reveals - News-Medical
Women with endometriosis-associated infertility are more likely to become pregnant, study reveals News-Medical
Published: July 2, 2025, 1:30 p.m.
Organon Provides Update on Phase 2 ELENA Proof-Of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain - MarketScreener
Organon Provides Update on Phase 2 ELENA Proof-Of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain MarketScreener
Published: July 2, 2025, 12:51 p.m.
Organon axes 'biggest potential opportunity' after flunking phase 2 trial - Fierce Biotech
Organon axes 'biggest potential opportunity' after flunking phase 2 trial Fierce Biotech
Published: July 2, 2025, 12:43 p.m.
Organon's Promising Endometriosis Drug OG-6219 Falls Short in Critical Phase 2 Trial, Program Discontinued - Stock Titan
Organon's Promising Endometriosis Drug OG-6219 Falls Short in Critical Phase 2 Trial, Program Discontinued Stock Titan
Published: July 2, 2025, 11:30 a.m.
Link copied to clipboard!